



## Vanta Bioscience Limited

Regd. Office : 1-20-248, Umajay Complex,  
Rasoolpura, Secunderabad - 500 003, INDIA.

Tel : +91 40 6657 5454, 2790 3226

Fax : +91 40 2790 8708

Website : www.vantabio.com

Email : info@vantabio.com

CIN No. : L74999TG2016PLC109280

To,  
The Corporate Relations Department,  
BSE Ltd.

November 11, 2021

### Sub: Outcome of Board Meeting held on November 11, 2021

We wish to inform you that the Board of Directors of the Company, at their just concluded meeting have inter alia, transacted the following businesses:

1. Approved the Standalone and Consolidated unaudited financials for the half year ended 30.09.2021 and took note of the Limited Review Reports issued by the Statutory Auditors.

The financial results and the limited review reports are annexed herewith.

2. Took note of resignation of Mr. Kiran Kumar Annabatula as Chief Financial Officer of the Company w.e.f 11.11.2021.
3. Appointment of Mr. Dokka Venkata Sathya Murali as Chief Financial Officer of the Company w.e.f 11.11.2021.

The information required to be submitted in terms of SEBI CIR/CFD/CMF/4/2015 dated September 09, 2015 for Item 2 and 3 above are annexed herewith.

The meeting commenced at 3.30 P.M. and concluded at 7:00 P.M.

This for your information and dissemination to the public.

For VANTA BIOSCIENCE LIMITED

Scrip Code: 540729 I Scrip ID: VANTABIO

MULAKALA DOPESH RAJA  
MANAGING DIRECTOR



In terms of SEBI CIR/CFD/CMF/4/2015 dated September 09, 2015, we hereby submit the following information:

<b>S. No</b>	<b>Particulars</b>	<b>Disclosure</b>
<b>1</b>	<b>Reason for change</b>	Mr. Dokka Venkata Sathya Murali has been appointed as CFO of the Company w.e.f 11.11.2021 in place of Mr. Kiran Kumar Annabatula who has resigned w.e.f the said date due to his pre-occupation.
<b>2</b>	<b>Date of Appointment / Cessation</b>	<b>11.11.2021</b> Mr. Dokka Venkata Sathya Murali has been appointed as CFO of the Company w.e.f 11.11.2021 in place of Mr. Kiran Kumar Annabatula who has resigned w.e.f the said date
<b>3</b>	<b>Brief Profile</b>	Mr. Dokka Venkata Sathya Murali is a MBA Finance from Sikkim Manipal University and has over 30 Years of Experience in Corporate Finance, Accounts, Statutory Compliance, Tax Planning, Budgeting etc.  He has earlier worked for Lanco Teesta Hydro Power Private Limited
<b>4</b>	<b>Disclosure of relationship</b>	NA





**MATHESH & RAMANA**  
CHARTERED ACCOUNTANTS

**Independent Auditor's Limited Review Report on unaudited standalone half yearly and year to date financial results of the Company**


**To The Board of Directors of  
Vanta Bioscience Limited**

1. We have reviewed the accompanying statement of Unaudited Standalone Financial Results of Vanta Bioscience Limited ("the Company") for the half year ended on 30<sup>th</sup> September, 2021 ("the statement"). This statement is the responsibility of the Company's Management and has been approved by the Company's Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion on the Statement is not modified in respect of the above matters.

For **MATHESH & RAMANA**  
CHARTERED ACCOUNTANTS

  
B. V. RAMANA REDDY  
M. No: 026967 Partner



**UIDN: 21026967AAAAON7148**

Place: Hyderabad  
Date: 11.11.2021

E-mail : mateshca@yahoo.co.in





**Independent Auditor's Limited Review Report on unaudited consolidated half yearly  
and year to date financial results of the Company**

**To The Board of Directors of  
Vanta Bioscience Limited**

1. We have reviewed the accompanying statement of Consolidated Unaudited Financial Results of Vanta Bioscience Limited ("the Parent") and its subsidiaries (the parent and its subsidiaries together referred as "the Group") for the half year ended on 30<sup>th</sup> September, 2021 ("the statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This statement is the responsibility of the Parent's Management and has been approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principle laid down in the Accounting Standard 25 "Interim Financial Reporting" ("AS 25"), prescribed under Section 133 of the companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:
  - a. Vanta Bioscience Limited- Parent Company
  - b. Vanta Clinical Research Limited- Subsidiary Company
  - c. Vayam Research Solutions Limited-Step Down Subsidiary Company
5. Based on our review conducted and procedure performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.

E-mail : mateshca@yahoo.co.in






**MATHESH & RAMANA**  
CHARTERED ACCOUNTANTS

6. The consolidated unaudited financial results includes the interim financial statements/ financial information/ financial results of 2 subsidiaries which have not been reviewed/audited by their auditors, whose interim financial statements/ financial information/ financial results reflect total assets of Rs. 3,097.29 Lakhs as at September 30, 2021, total revenues of Rs. Nil for the half year ended September 30, 2021, total net profit after tax of Rs. (60.69) Lakhs and cash flows (net outflow) of Rs. (115.06) Lakhs for the period from 1<sup>st</sup> April, 2021 to 30<sup>th</sup> September, 2021, as considered in the consolidated unaudited financial results. According to the information and explanations given to us by the Management, these interim financial statements / financial information / financial results are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matters.

For **MATHESH & RAMANA**  
CHARTERED ACCOUNTANTS

  
**B. V. RAMANA REDDY**  
M. No: 026967 Partner



**UIDN: 21026967AAAAOO9249**

Place: Hyderabad  
Date: 11.11.2021





## Vanta Bioscience Limited

Regd. Office : 1-20-248, Umajay Complex,  
Rasoolpura, Secunderabad - 500 003, INDIA.  
Tel : +91 40 6657 5454, 2790 3226  
Fax : +91 40 2790 8708  
Website : www.vantabio.com  
Email : info@vantabio.com  
CIN No. : L74999TG2016PLC109280

VANTA BIOSCIENCE LIMITED					
NO.02/G/308/G NO.3/FF/SF/1-20-248 UMAJAY COMPLEX RASOOLPURA SECUNDERABAD - 500003					
CIN L74999TG2016PLC109280					
STATEMENT OF STANDALONE AND CONSOLIDATED UNAUDITED RESULTS FOR THE HALF YEAR ENDED 30th SEPTEMBER 2021					
(Rupees. In Lacs)					
Sr.No	Particulars	STANDALONE			
		HALF YEAR ENDED			YEAR ENDED
		30.09.2021	30.09.2020	31.03.2021	31.03.2021
		(Un Audited)	(Un Audited)	(Audited)	(Audited)
1	Income				
	Revenue from Operation	538.21	527.59	476.25	1003.84
	Other Income	2.10	0.000	2.15	2.15
	Total Revenue	540.31	527.595	478.40	1005.99
2	Expenses				
	a) Cost of material Consumed	55.66	52.71	29.17	81.88
	b) Employee Benfit Expenses	184.76	147.33	135.32	282.65
	c) Financial Cost	102.24	101.45	104.40	205.85
	d) Depreciation and amortization Exp	65.82	60.60	64.55	125.15
	e) other expenses	100.02	152.45	97.51	249.96
	Total Expenses	508.50	514.54	430.95	945.49
	Profit/(Loss) from ordinary activities before				
3	Exceptional Items (1-2)	31.81	13.05	47.45	60.50
4	Exceptional Items Income /(Expenses)	0.00	0.00	0.00	0.00
	Profit/(Loss) from oridnary activities before tax				
5	(3+4)	31.81	13.05	47.45	60.50
6	Tax Expenses				
	a) Current Tax	(5.04)	(2.16)	(7.55)	(9.71)
	b) MAT Credit Availied	0.97	0.00	9.41	9.41
	c) Deferred Tax	(2.91)	(6.54)	(6.63)	(13.17)
7	Net Profit/(Loss) from ordinary activities after tax (5-6)	24.83	4.35	42.68	47.03
8	Other Comprehensive Income / (expenses) for the year, net of tax	0.00	0.00	0.00	0.00
9	Total Comprehensive Income/(Loss) Net of Tax (7+8)	24.83	4.35	42.68	47.03
10	Paid up Equity share capital (face value of Rs.10/- )	631.20	631.20	631.20	631.20
11	Reserve excluding Revaluation reserve				
12	Earning per share of (before extra ordinary items)				
	Rs.10 Each (Not Anualised)				
	a) Basic (Rs.)	0.39	0.07	0.68	0.75
	b) Diluted (Rs.)	0.39	0.07	0.68	0.75
	Earning per share of after extra ordinary items)				
	Rs.10 Each (Not Anualised)				
	a) Basic (Rs.)	0.39	0.07	0.68	0.75
	b) Diluted (Rs.)	0.39	0.07	0.68	0.75

For and on behalf of Board of Directors

*Dopesh Raja Mulakala*

Dopesh Raja Mulakala  
Managing Director

Research Center :  
K2-B, 11<sup>th</sup> Cross Street, SIPCOT Industrial Complex,  
Gummidipoondi, Thiruvallur District, Tamilnadu - 601 201.  
Tel : 044 6790 1600

Place : Hyderabad  
Date : 11.11.2021

The Right Dose of  
Intelligent Toxicology





## Vanta Bioscience Limited

Regd. Office : 1-20-248, Umajay Complex,  
Rasoolpura, Secunderabad - 500 003, INDIA.  
Tel : +91 40 6657 5454, 2790 3226  
Fax : +91 40 2790 8708  
Website : www.vantabio.com  
Email : info@vantabio.com  
CIN No. : L74999TG2016PLC109280

VANTA BIOSCIENCE LIMITED					
NO.02/G/308/G NO.3/FF/SF/1-20-248 UMAJAY COMPLEX RASOOLPURA SECUNDERABAD - 500003					
CIN L74999TG2016PLC109280					
STATEMENT OF STANDALONE AND CONSOLIDATED UNAUDITED RESULTS FOR THE HALF YEAR ENDED 30th SEPTEMBER 2021					
(Rupees. In Lacs)					
Sr.No	Particulars	CONSOLIDATED			
		HALF YEAR ENDED			YEAR ENDED
		30.09.2021	30.09.2020	31.03.2021	31.03.2021
		(Un Audited)	(Un Audited)	(Audited)	(Audited)
1	<b>Income</b>				
	Revenue from Operation	538.22	527.59	476.24	1003.83
	Other Income	2.17	0.02	3.43	3.45
	<b>Total Revenue</b>	<b>540.39</b>	<b>527.61</b>	<b>479.67</b>	<b>1007.28</b>
2	<b>Expenses</b>				
	a) Cost of material Consumed	55.66	52.71	29.17	81.88
	b) Employee Benfit Expenses	184.76	147.84	134.81	282.65
	c) Financial Cost	114.30	101.45	112.51	213.96
	d) Depreciation and amortization Exp	65.82	60.60	64.55	125.15
	e) other expenses	148.74	149.04	95.68	244.72
	<b>Total Expenses</b>	<b>569.28</b>	<b>511.64</b>	<b>436.72</b>	<b>948.36</b>
	<b>Profit/(Loss) from ordinary activities before</b>				
3	<b>Exceptional Items (1-2)</b>	<b>-28.89</b>	<b>15.98</b>	<b>42.94</b>	<b>58.92</b>
4	Exceptional Items Income /(Expenses)	0.00	0.00	0.00	0.00
5	<b>Profit/(Loss) from ordinary activities before tax (3+4)</b>	<b>-28.89</b>	<b>15.98</b>	<b>42.94</b>	<b>58.92</b>
6	<b>Tax Expenses</b>				
	a) Current Tax	32.80	(3.51)	(6.69)	(10.20)
	b) MAT Credit Availed	0.97	0.00	9.41	9.41
	c) Deferred Tax	(2.91)	(6.54)	(6.63)	(13.17)
7	<b>Net Profit/(Loss) from ordinary activities after tax (5-6)</b>	<b>1.97</b>	<b>5.92</b>	<b>39.03</b>	<b>44.95</b>
8	Other Comprehensive Income / (expenses) for the year, net of tax	0.00	0.00	0.00	0.00
9	<b>Total Comprehensive Income/(Loss) Net of Tax (7+8)</b>	<b>1.97</b>	<b>5.92</b>	<b>39.03</b>	<b>44.95</b>
10	Paid up Equity share capital (face value of Rs.10/-)	631.20	631.20	631.20	631.20
11	<b>Reserve excluding Revaluation reserve</b>				
12	Earning per share of (before extra ordinary items)				
	Rs.10 Each (Not Anualised)				
	a) Basic (Rs.)	0.03	0.09	0.62	0.71
	b) Diluted (Rs.)	0.03	0.09	0.62	0.71
	Earning per share of after extra ordinary items)				
	Rs.10 Each (Not Anualised)				
	a) Basic (Rs.)	0.03	0.09	0.62	0.71
	b) Diluted (Rs.)	0.03	0.09	0.62	0.71

For and on behalf of Board of Directors

*Dopesh Raja*

Dopesh Raja Mulakala  
Managing Director



Place : Hyderabad  
Date : 11.11.2021

The Right Dose of  
Intelligent Toxicology

Research Center :  
K2-B, 11<sup>th</sup> Cross Street, SIPCOT Industrial Complex,  
Gummidipoondi, Thiruvallur District, Tamilnadu - 601 201.  
Tel : 044 6790 1600



## Vanta Bioscience Limited

Regd. Office : 1-20-248, Umajay Complex,  
Rasoolpura, Secunderabad - 500 003, INDIA.  
Tel : +91 40 6657 5454, 2790 3226  
Fax : +91 40 2790 8708  
Website : www.vantabio.com  
Email : info@vantabio.com  
CIN No. : L74999TG2016PLC109280

VANTA BIOSCIENCE LIMITED					
NO.02/G/308/G NO.3/FF/SF/1-20-248 UMAJAY COMPLEX RASOOLPURA SECUNDERABAD - 500003					
CIN L74999TG2016PLC109280					
STATEMENT OF ASSETS & LIABILITIES AS ON 30th SEPTEMBER 2021					
Sr.No.	Particulars	STANDALONE		CONSOLIDATED	
		30.09.2021	31.03.2021	30.09.2021	31.03.2021
		Un Audited	Audited	Un Audited	Audited
A	<b>Equity and Liabilities</b>				
1	<b>EQUITY</b>				
	a) Equity share capital	631.20	631.20	631.20	631.20
	b) Reserve & Surplus	1784.66	1759.83	1762.66	1760.68
	c) Non Controlling/Minority Interest	0.00	0.00	495.41	230.85
	<b>Sub total Equity</b>	<b>2415.86</b>	<b>2391.03</b>	<b>2889.27</b>	<b>2622.73</b>
	<b>LIABILITIES</b>				
2	<b>Non Current Liabilities</b>				
	a) Financial Liabilities				
	i) Borrowings	1581.35	1076.74	3250.26	2783.63
	b) Provisions		0.00	0.00	0.00
	c) Deferred tax Liabilities	75.15	72.24	75.15	72.25
	d) Other Non Current Liabilities		0.00	0.00	0.00
	<b>Sub Total -Non Current Liabilities</b>	<b>1656.50</b>	<b>1148.98</b>	<b>3325.41</b>	<b>2855.88</b>
3	<b>Current Liabilities</b>				
	a) Financial Liabilities				
	i) Borrowings	355.14	253.02	558.44	415.20
	ii) Trade Payables	47.90	46.50	60.54	46.50
	b) Other Current Liabilities	349.24	779.70	682.46	1016.43
	c) Provisions	2.52	5.56	2.52	6.18
	d) Current tax Liabilities(net)	0.00	0.00	0.00	0.00
	<b>Sub Total -Non Current Liabilities</b>	<b>754.80</b>	<b>1084.78</b>	<b>1303.96</b>	<b>1484.31</b>
	<b>Total Equity and Liabilities</b>	<b>4827.16</b>	<b>4624.79</b>	<b>7518.64</b>	<b>6962.92</b>
B	<b>ASSETS</b>				
1	<b>Non Current Assets</b>				
	a) Property, Plant and Equipment	1504.73	1551.92	1504.73	1551.92
	b) Capital Work in Progress	0.00		2437.13	1934.00
	c) Other Intangible assets	1510.44	1386.61	1510.44	1386.61
	d) Other Intangible assets under development	0.00	0.00	0.00	0.00
	e) Investment in associates and joint ventures	0.00	0.00	0.00	0.00
	f) Financial Assets	0.00	0.00	0.00	0.00
	i) Investments in Subsidiary	300.00	300.00	0.00	0.00
	ii) Loans	0.00	0.00	0.00	0.00
	iii) Other Financial Assets	0.00	0.00	0.00	0.00
	g) Deferred tax assets (net)	0.00	0.00	0.00	0.00
	h) Other non current assets	27.48	35.04	89.62	96.76
	<b>Sub Total Non-CurrentAssets</b>	<b>3342.65</b>	<b>3273.57</b>	<b>5541.92</b>	<b>4969.29</b>
2	<b>Current Assets</b>				
	a) Inventories	976.60	976.42	976.60	976.42
	<b>b) Financial Assets</b>				
	i) Investments	0.00	0.00	0.00	0.00
	ii) Trade Receivable	308.22	197.93	314.80	201.49
	iii) Bank, Cash and Cash equivalents	5.77	6.67	149.07	265.03
	iv) Loans & Advances	145.03	126.28	483.02	486.65
	iv) Othe Financial Assets	0.00	0.00	0.00	0.00
	c) Current Tax Assets (net)	0.00	0.00	0.00	0.00
	d) Other Current Assets	48.89	43.92	53.23	64.04
	<b>Sub Total Current Assets</b>	<b>1484.51</b>	<b>1351.22</b>	<b>1976.72</b>	<b>1993.63</b>
	<b>Total Assets</b>	<b>4827.16</b>	<b>4624.79</b>	<b>7518.64</b>	<b>6962.92</b>

For and on behalf of Board of Directors

  
Dopesh Raja Mulakala  
Managing Director

Research Center

040-176660  
K2-B, 11<sup>th</sup> Cross Street, SPCOT Industrial Complex,  
Gummidipoondi, Thiruvallur District, Tamilnadu - 601 201.  
Tel : 044 6790 1600

Place : Hyderabad  
Date : 11.11.2021







# Vanta Bioscience Limited

Regd. Office : 1-20-248, Umajay Complex,  
Rasoolpura, Secunderabad - 500 003, INDIA.  
Tel : +91 40 6657 5454, 2790 3226  
Fax : +91 40 2790 8708  
Website : www.vantabio.com  
Email : info@vantabio.com  
CIN No. : L74999TG2016PLC109280

VANTA BIOSCIENCE LIMITED				
Cash Flow statement for the period ended 30th SEPTEMBER,2021				
Particulars	STANDALONE		CONSOLIDATED	
	For the Half	For the Year	For the Half	For the Year
	Year ended	ended	Year ended	ended
	30.09.2021	31.03.2021	30.09.2021	31.03.2021
<b>A. Cash Flow from Operating Activities</b>				
Profit before exceptional , Extraordinary items and Tax	31.81	60.50	(28.89)	58.92
<b>Adjustment for:</b>				
Depreciation	65.82	125.15	65.82	125.15
Finance Charges	102.24	205.85	114.30	213.96
Profit on Sale of Fixed Assets	-	(2.15)	-	(2.15)
<b>Sub total</b>	<b>168.06</b>	<b>328.85</b>	<b>180.12</b>	<b>336.96</b>
<b>Operating profit Before Working Capital Changes</b>	<b>199.87</b>	<b>389.35</b>	<b>151.23</b>	<b>395.88</b>
<b>Adjustment for:</b>				
(Increase) /Decrease in Inventories	(0.17)	424.31	(0.17)	424.31
(Increase) /Decrease in Trade receivables	(110.29)	(62.34)	(113.31)	(62.34)
Increase /(Decrease) in Current Liabilities	(432.10)	307.37	(323.59)	55.40
(Increase) /Decrease Loans & Advances	(15.18)	42.13	22.56	(116.06)
(Increase) /Decrease in Current Investment	-	-	-	-
<b>Sub total</b>	<b>(557.74)</b>	<b>711.47</b>	<b>(414.51)</b>	<b>301.31</b>
<b>Cash Generated from operations</b>	<b>(357.87)</b>	<b>1,100.82</b>	<b>(263.28)</b>	<b>697.19</b>
<b>Net Cash Flow from Operating Activities</b>	<b>(357.87)</b>	<b>1,100.82</b>	<b>(263.28)</b>	<b>697.19</b>
<b>B: Cash Flow from Investing Activities</b>				
Purchase of Fixed Assets	(18.63)	(87.72)	(18.63)	(85.52)
Capital Work In progress	-	-	-	-
Capital Work In progress-R&D	(123.84)	(900.38)	(626.97)	(2,133.91)
proceeds from sale of Fixed Assets	-	2.20	-	-
Investment in Subsidiaries	-	-	-	-
Purchase of other Non current Investments	-	-	-	-
<b>Net Cash Flow from Investing Activities</b>	<b>(142.47)</b>	<b>(985.90)</b>	<b>(645.60)</b>	<b>(2,219.43)</b>
<b>C: Cash Flow from Financing Activities</b>				
Increase /(Decrease) in Unsecured Loan	-	-	-	450.10
Increase /(Decrease) in Working capital	102.10	64.63	143.23	226.81
Increase /(Decrease) in Term Loan	504.62	34.01	466.63	1,183.13
Increase /(Decrease) in share capital	-	-	302.40	132.00
Increase /(Decrease) in share Premium	-	-	-	-
Finance Charges	(102.24)	(205.85)	(114.30)	(213.96)
<b>Net Cash Flow from Financing Activities</b>	<b>504.48</b>	<b>(107.21)</b>	<b>797.96</b>	<b>1,778.08</b>
Actual Payment of Income Tax	(5.04)	(9.71)	(5.04)	(10.32)
<b>D: Net Increase/Decrease in Cash and cash Equivalents</b>	<b>(0.90)</b>	<b>(2.00)</b>	<b>(115.96)</b>	<b>245.52</b>
<b>Opening of Cash &amp; Cash Equivalents</b>	<b>6.67</b>	<b>8.67</b>	<b>265.03</b>	<b>19.51</b>
<b>Closing Balance of Cash &amp; Cash Equivalents</b>	<b>5.77</b>	<b>6.67</b>	<b>149.07</b>	<b>265.03</b>
See accompanying notes to the financial statements				
As per our report of even date annexed.				
<div> <div>Place : Hyderabad Date : 11.11.2021</div> <div> For and on behalf of Board of Directors    Dopesh Raja Mulakala  Managing Director  DIN:01176660 </div> </div>				



## Vanta Bioscience Limited

Regd. Office : 1-20-248, Umajay Complex,  
Rasoolpura, Secunderabad - 500 003, INDIA.  
Tel : +91 40 6657 5454, 2790 3226  
Fax : +91 40 2790 8708  
Website : [www.vantabio.com](http://www.vantabio.com)  
Email : [info@vantabio.com](mailto:info@vantabio.com)  
CIN No. : L74999TG2016PLC109280

### Notes to Standalone and consolidated financial statements:

1. The above said financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 11<sup>th</sup> November, 2021.
2. The Statutory Auditors have carried out limited review of the Un Audited Results of the company for the half year ended 30.09.2021.
3. The statement are prepared in accordance with the requirements of accounting standards (AS) specified under section 133 of Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules 2014.
4. As per MCA Notification dated 16th February 2015, the companies whose shares are listed on BSE SME platform as referred to in chapter XB of SEBI (Issue of Capital and Disclosure requirements) regulations, 2009 are exempted from the Compulsory requirement of adoption of IND—AS. As the company is covered under exempted from the Compulsory requirement of adoption of IND As. Hence it has not adopted IND AS for preparation of Financial Statements.
5. Statement of Assets and Liabilities as on 30<sup>th</sup> September 2021 is enclosed herewith.
6. Statement of Cash flow for the period ended 30<sup>th</sup> September 2021 is enclosed herewith.
7. The financial figures for the previous half year/year have been regrouped/reclassified wherever necessary to confirm to current period.
8. The Company is engaged in the business of full service preclinical contract Research organization. Hence there is no separate segment reporting required

### 9. Impact of Covid-19 on Business of the company

It is envisaged that impact of the COVID-19 pandemic, including that on financial condition and results of operations, future operations, capital and financial resources, liquidity, assets, internal financial control over financial reporting and disclosure controls and procedures, demand for products/services etc. is significant in case of our company.

Though, there has been a lag in receivables from clients and also in availability of raw material for conducting some specific studies due to restriction placed on movement and transportation. However, there is no long term major impact as such on the overall set up and functioning of the Company as on date.

Further, it is anticipated that with work and transportation related relaxations being notified for various parts of the country and gradual start of economic activities would eventually result in cash flows and availability of raw materials as and when required for continuation of our studies.

10. The said results are uploaded on the website of the Company [www.vantabio.com](http://www.vantabio.com) and on BSE Ltd.



The Right Dose of  
Intelligent Toxicology

Research Center :  
K2-B, 11<sup>th</sup> Cross Street, SIPCOT Industrial Complex,  
Gummidipoondi, Thiruvallur District, Tamilnadu - 601 201.  
Tel : 044 6790 1600